B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases

Shiori Kondo, Tomoyuki Akashi, Hitoshi Katsuta, Ryuichi Iwakiri, Keizo Anzai, Seiho Nagafuchi, Yoshiyuki Niho, Mine Harada

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)

Abstract

The levels and types of immune responses are determined dependent on the extent of pathogen invasion, reactions to antigens mediated by macrophage-dendritic cells, T cells and antibodies. Recently, accumulating evidence suggests that B cells also play an important role in the regulation of immune responses. Here we have made a review to present a role of B cells in determining the level of immune responses and discussed about the clinical significance of B cell-targeted therapy in patients with autoimmune diseases. Type 1 diabetes is a T cell-mediated autoimmune disease characterized by the destruction of insulin-producing pancreatic beta cells. We and other groups have elucidated that B cells play a critical role in the development of insulitis and diabetes, as B-cell-deficient NOD mice are protected from developing type 1 diabetes. B cells are essential for the T cell receptor clonotype spreading of islet-infiltrating T cells, indicating that B cells may play a role in determining the level of immune responses by antigen presentation to antigen specific T cells. There are now numerous case reports and small series of clinical trials regarding rituximab therapy in autoimmune diseases, such as refractory autoimmune hemolytic anemia, IgM antibody-associated polyneuropathy, systemic lupus erythematosus and rheumatoid arthritis. Rituximab is a genetically engineered chimeric anti-CD 20 monoclonal antibody that is approved for the treatment of lymphoma. CD20 is a B-cell surface antigen that is expressed only on pre- B and mature B cells. Thus, rituximab causes a selective transient depletion of the CD20+ B -cell subpopulation. Rationale and strategy for targeting B cells in the treatment of autoimmune diseases consist of the inhibition of antigen-presentation and co-stimulation that induces T cell expansion and activation. Further careful mechanistic studies are required to develop therapies in patients with autoimmune diseases.

Original languageEnglish
Pages (from-to)86-92
Number of pages7
JournalFukuoka igaku zasshi = Hukuoka acta medica
Volume96
Issue number4
Publication statusPublished - Jan 1 2005
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of 'B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases'. Together they form a unique fingerprint.

Cite this